Clinical trials: Cytarabine, completed
Adult Acute Lymphoblastic Leukemia in Remission
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia.
- Trial name
- NCT00039377
- Testing
- imatinib mesylate, methotrexate, vincristine sulfate
- Where
- 97 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ofatumumab in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and dexamethasone alternating with ofatumumab in combination with cytarabine and methotrexate…
- Conditions
- Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma
- Trial name
- NCT01527149
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia
Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with CACAG regimen in the treatment of newly diagnosed acute myeloid leukemia.
- Trial name
- NCT05659992
- Testing
- azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Acute Myeloid Leukemia (AML)
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00093600
- Testing
- cytarabine, daunorubicin hydrochloride, midostaurin
- Where
- 6 sites in United States, Germany
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Central Nervous System Lymphoma
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.
- Trial name
- NCT01458730
- Testing
- Immunochemotherapy
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- University of Aarhus
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma
- Trial name
- MITCL (NCT01842672)
- Testing
- Clofarabine, Mitoxantrone
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- New York Medical College
Lymphoma, Large-Cell, Diffuse
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated…
- Trial name
- NCT00137995
- Testing
- Rituximab, Etoposide, Carboplatine
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 481 people
- Sponsor
- Lymphoma Study Association
Acute Myeloid Leukemia
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC.
- Trial name
- NCT02920008
- Testing
- guadecitabine, Treatment Choice (TC)
- Where
- 95 sites in United States, Belgium and 13 more
- Volunteers
- 302 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Lymphoblastic Leukemia
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
The primary objective of this study (TOTXVI) is to compare the clinical benefit, the pharmacokinetics, and the pharmacodynamics of polyethylene glycol-conjugated (PEG) asparaginase given in higher dose (HD PEG) versus those of…
- Trial name
- NCT00549848
- Testing
- Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- St. Jude Children's Research Hospital
Novo Acute Myeloid Leukemia
Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Acute myeloid leukemia (AML) is a neoplasm of immature hematopoietic cells (blasts) with altered ripening capacity. Due to excessive proliferation, the blasts displace normal hematopoietic cells and bone marrow failure appears.
- Trial name
- NCT01698879
- Testing
- Mylotarg
- Where
- 6 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Leukemia
Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy.
- Trial name
- NCT00540956
- Testing
- cytarabine, laboratory biomarker analysis
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut Paoli-Calmettes
Lymphoma, Non-Hodgkin, HIV Infections
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine (AZT) treatment for patients with peripheral lymphoma.
- Trial name
- NCT00000703
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Follicular Lymphoma
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
Follicular lymphoma has historically been considered an incurable lymphoma. By combining multiple effective treatments, the investigators believe that prolonged disease-free survival is achievable in this disease.
- Trial name
- MasterPlan (NCT01130194)
- Testing
- Combination of treatment modalities
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- St. Louis University
Acute Myeloid Leukemia
GRASPA Treatment for Patients With Acute Myeloblastic Leukemia
The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) to standard chemotherapy (low-dose cytarabine) to treat patients older than 65 years diagnosed with AML and unfit for intensive…
- Trial name
- ENFORCE (NCT01810705)
- Testing
- GRASPA
- Where
- 21 sites in France
- Volunteers
- 123 people
- Sponsor
- ERYtech Pharma
Acute Myeloid Leukemia
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML).
- Trial name
- NCT00926731
- Testing
- AZD1152, LDAC (low dose cytosine arabinoside)
- Where
- 4 sites in United States, France
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination…
- Trial name
- NCT02909972
- Testing
- ALRN-6924, ALRN-6924 in combination with cytarabine
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Aileron Therapeutics, Inc.
Scleroderma, Systemic, Interstitial Lung Disease
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
- Trial name
- SLSIII (NCT03221257)
- Testing
- Pirfenidone (PFD), Mycophenolate Mofetil (MMF)
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- Michael Roth
Leukemia
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells.
- Trial name
- NCT00005945
- Testing
- cyclophosphamide, cytarabine, daunorubicin hydrochloride
- Where
- 130 sites in United States, Australia and 3 more
- Volunteers
- 3,054 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients. PF-04449913 will be administered orally as a single agent in patients with select advanced hematologic malignancies, or in combination with…
- Trial name
- NCT02038777
- Testing
- PF-04449913, Low dose ARA-C (LDAC), Daunorubicin
- Where
- 9 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00039130
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 31 sites in United States
- Volunteers
- 105 people
- Sponsor
- Alliance for Clinical Trials in Oncology